Analysts’ Opinions Are Mixed on These Healthcare Stocks: Audentes Therapeutics (BOLD) and Novavax (NVAX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Audentes Therapeutics (NASDAQ:BOLD) and Novavax (NASDAQ:NVAX).

Audentes Therapeutics (BOLD)

In a report issued on October 5, Madhu Kumar from B.Riley FBR reiterated a Sell rating on Audentes Therapeutics, with a price target of $20. The company’s shares closed on Friday at $36.64.

Kumar wrote:

“This morning, 10/5, Audentes Therapeutics (BOLD) announced additional data from the Phase I/II ASPIRO trial from its lead asset, myotubularin 1 (MTM1) adeno-associated virus gene therapy (AAV X-linked myotoubular myopathy (XLMTM) at the World Muscle Society (WMS) in Argentina (the company’s presentation on these results can be found here). While generally consistent with previous results, we continue to believe current BOLD share prices have priced beyond perfection the opportunity in XLMTM, representing significant over- valuation. We thus reiterate our BOLD Sell rating and $20 price target.”

According to, Kumar is a 5-star analyst with an average return of 20.5% and a 48.3% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Arbutus Biopharma Corporation, and Clementia Pharmaceuticals Inc.

Currently, the analyst consensus on Audentes Therapeutics is a Moderate Buy with an average price target of $40.

See today’s analyst top recommended stocks >>

Novavax (NVAX)

B.Riley FBR analyst George Zavoico reiterated a Buy rating on Novavax today and set a price target of $10. The company’s shares closed on Friday at $2.07.

Zavoico observed:

“With the expected completion of two key ongoing clinical trials in 1Q19 that could be transformative for Novavax (NVAX) if the results are positive, we reiterate our Buy rating and $10 per share 12-month price target and make NVAX our Alpha Generator pick. The Prepare Phase III trial of a respiratory syncytial virus (RSV) F protein vaccine, called “ResVax,” enrolled the 4,636th pregnant woman in May, of which at least 3,000 received ResVax. The last baby was born by August, starting the clock for a 180-day follow-up safety and efficacy assessment. Based on positive results of an informational analysis that Prepare announced early this year, and reported by us here, FDA agreed that this will be the final analysis of Prepare.”

According to, Zavoico is a 3-star analyst with an average return of 3.4% and a 46.3% success rate. Zavoico covers the Healthcare sector, focusing on stocks such as Cellular Biomedicine Group, Catalyst Biosciences Inc, and Actinium Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Novavax with a $2 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

From Our Partners